Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Cytochrome p450 3a4

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    11 result(s) found for: Cytochrome p450 3a4. Displaying page 1 of 1.
    EudraCT Number: 2016-001440-18 Sponsor Protocol Number: IACI2016 Start Date*: 2018-05-30
    Sponsor Name:university medical center utrecht
    Full Title: Pharmacokinetic interactions between ivacaftor and cytochrome P450 3A4 inhibitors in cystic fibrosis patients and healthy controls
    Medical condition: cystic fibrosis and healthy subjects
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2022-000082-41 Sponsor Protocol Number: 2021-0486 Start Date*: 2022-03-31
    Sponsor Name:Fundación para la Investigación en Urología
    Full Title: Impact of pitavastatin use in prostate cancer patients treated with new generation androgen therapy: multicenter clinical trial
    Medical condition: We propose a multicenter, prospective, randomized, single-blind clinical trial, without conflict of interest, to determine the clinical benefit of statins (Pitavastatin 2 mg) in prostate cancer pa...
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2022-003265-38 Sponsor Protocol Number: PTC743-NEU-005-FA Start Date*: 2022-10-22
    Sponsor Name:PTC Therapeutics, Inc.
    Full Title: An Open-Label Study to Evaluate Pharmacokinetics, Safety, and Efficacy of Vatiquinone in Children With Friedreich Ataxia Younger Than 7 Years of Age
    Medical condition: Friedreich Ataxia
    Disease:
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: (No results available)
    EudraCT Number: 2009-012802-38 Sponsor Protocol Number: UMCNONCO200903 Start Date*: 2009-07-01
    Sponsor Name:University Medical Centre Nijmegen St Radboud
    Full Title: Evaluation of the activity of temsirolimus with FLT-PET in patients with renal cell cancer
    Medical condition: advanced (stage IV or recurrent disease) RCC
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-003688-73 Sponsor Protocol Number: D9170C00001 Start Date*: 2019-09-10
    Sponsor Name:AstraZeneca AB
    Full Title: A Phase I/IIa, Open-Label Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Ascending Doses of AZD7648 Monotherapy or in Combination with either Cytotoxic Chemo...
    Medical condition: Advanced Malignancies
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033128 Ovarian cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006187 Breast cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2020-002812-36 Sponsor Protocol Number: PTC743-NEU-003-FA Start Date*: 2021-02-18
    Sponsor Name:PTC Therapeutics, Inc.
    Full Title: A Randomized, Parallel-Arm, Double-Blind, Placebo-Controlled Study with Open-Label Extension to Assess the Efficacy and Safety of Vatiquinone for the Treatment of Friedreich ataxia (MOVE-FA)
    Medical condition: Friedreich Ataxia (FA)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10017374 Friedreich's ataxia PT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: DE (Completed) ES (Ongoing) FR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2012-004083-21 Sponsor Protocol Number: E7438-G000-101 Start Date*: 2015-02-02
    Sponsor Name:Epizyme, Inc.
    Full Title: An Open-Label, Multicenter, Phase 1/2 Study of Tazemetostat (EZH2 Histone Methyl Transferase [HMT] Inhibitor) as a Single Agent in Subjects With Advanced Solid Tumors or With B Cell Lymphomas
    Medical condition: Relapsed or refractory Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Advanced solid tumor
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2013-004000-19 Sponsor Protocol Number: PAC326 Start Date*: 2014-05-12
    Sponsor Name:CTI BioPharma Corp.
    Full Title: A Randomized Controlled Phase 3 Study of Oral Pacritinib versus Best Available Therapy in Patients with Thrombocytopenia and Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Ess...
    Medical condition: Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis with Thrombocytopenia
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10028537 Myelofibrosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Prematurely Ended) GB (Completed) DE (Temporarily Halted) HU (Prematurely Ended) CZ (Prematurely Ended) NL (Temporarily Halted) FR (Completed)
    Trial results: View results
    EudraCT Number: 2020-004610-35 Sponsor Protocol Number: AL-2001 Start Date*: 2021-03-16
    Sponsor Name:Allarity Therapeutics Europe Aps
    Full Title: Phase II, open label, single arm study to investigate anti-tumor effect of ixabepilone in patients with locally recurrent metastatic breast cancer (mBC) selected by the ixabepilone Drug Response Pr...
    Medical condition: Locally recurrent or metastatic breast cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006187 Breast cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed) PL (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2020-006118-19 Sponsor Protocol Number: 2020-012-00EU1 Start Date*: 2021-05-04
    Sponsor Name:Hutchison MediPharma Limited
    Full Title: An Open-Label Phase 2 Study of Surufatinib in Patients with Neuroendocrine Tumours in Europe
    Medical condition: Neuroendocrine Tumours
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052399 Neuroendocrine tumour PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) DE (Completed) NO (Completed) IT (Completed) ES (Temporarily Halted)
    Trial results: (No results available)
    EudraCT Number: 2012-004239-21 Sponsor Protocol Number: PAC325 Start Date*: 2012-12-03
    Sponsor Name:CTI BioPharma Corp.
    Full Title: A Randomized Controlled Phase 3 Study of Oral Pacritinib versus Best Available Therapy in Patients with Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemi...
    Medical condition: Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis
    Disease: Version SOC Term Classification Code Term Level
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10028537 Myelofibrosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Prematurely Ended) GB (Completed) CZ (Prematurely Ended) HU (Prematurely Ended) DE (Completed) IT (Prematurely Ended)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 02 19:01:31 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA